The Generalist
For decades, drug discovery has shifted away from nature and toward biology-first approaches. Viswa Colluru believes that shift was a catastrophic mistake. His company, Enveda Biosciences, has raised over $500 million to build a “search engine for nature’s chemistry.” The mission is personal: he grew up around his father’s pharmacy in India and later lost his mother to a treatable cancer whose medicine his family couldn’t afford. Many life-changing medicines, including morphine, aspirin, and metformin, originated in nature, but there has never been a reliable, scalable way to systematically explore its chemistry. Colluru founded Enveda in 2019 with $55,000 of his own savings to change that. The company has since identified 18 drug candidates, with three now in clinical trials. In our conversation, we explore: * Why the pharmaceutical industry abandoned nature (and why that was a massive mistake) * How Enveda built a system to decode unknown molecules in nature * The deeply personal story of his mother’s battle with leukemia and how it shaped his life’s work * Why old ideas, from immunotherapy to natural products, often hold the most latent potential * How Enveda developed 18 drug candidates for about $1 million each instead of $10-15 million * Enveda’s three leading drug candidates targeting eczema, obesity, and ulcerative colitis * Why first-in-class medicines capture the vast majority of returns in pharma * What competitive table tennis taught him about building companies — Thank you to the partners who make this possible Brex [https://www.brex.com/mario]: The intelligent finance platform. Ahrefs Brand Radar [https://ahrefs.com/generalist]: Find your brand in AI results. Persona [https://withpersona.com/generalist]: Trusted identity verification for any use case. — Timestamps (00:00) Introduction to Viswa Colluru (03:57) His father’s pharmacy and early exposure to Western and Ayurvedic medicine (07:06) Early pull toward technology (09:29) His mother’s leukemia diagnosis (14:24) Studying Biotechnology (16:07) Graduate school (17:55) Studying immunotherapy when it was unfashionable (24:23) Innovation vs. novelty (27:24) Lessons from table tennis (32:05) Joining Recursion (37:10) Learning urgency and courage (40:42) What launched Enveda (45:40) The limits of reductionist drug discovery (49:53) Chemistry-first approach (52:17) Raising $225K and investing $55K personally (56:04) Initial studies and targets (1:04:30) Three categories of leading drugs: Eczema, obesity, ulcerative colitis (1:13:27) Why GLP-1s are not the whole answer (1:18:27) Enveda’s long-term vision (1:21:31) Book recommendation — Follow Viswa Colluru LinkedIn: https://www.linkedin.com/in/viswacolluru [https://www.linkedin.com/in/viswacolluru] X: https://x.com/viswacolluru [https://x.com/viswacolluru] — Resources and episode mentions: https://www.generalist.com/p/the-future-of-drug-discovery [https://www.generalist.com/p/the-future-of-drug-discovery] — Production and marketing by penname.co [https://penname.co/]. For inquiries about sponsoring the podcast, email jordan@penname.co.
44 episodios
Comentarios
0Sé la primera persona en comentar
¡Regístrate ahora y únete a la comunidad de The Generalist!